Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a gut molecule shield nerve fibers in MS?

NCT ID NCT06402487

Symptom relief Sponsor: Salzburger Landeskliniken Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Researchers are testing whether propionic acid, a short-chain fatty acid, can slow nerve damage and ease fatigue in people with multiple sclerosis. The trial enrolls 101 adults aged 18 to 60 who have stable MS and signs of immune activity in their spinal fluid. Participants receive either propionic acid capsules or a placebo alongside their usual MS treatment. The study measures blood markers of nerve and brain cell damage, plus fatigue, walking speed, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
propionic acid, a short-chain fatty acid taken as a dietary supplement capsule
What this could lead to
If it works, propionic acid could become a low-cost supplement added to standard MS treatment to protect nerve fibers and reduce fatigue.
What could go wrong
This is a mid-stage trial in 101 people, so results may not hold in larger groups. Supplements can interact with other treatments, and the study may show no benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

101 people

The number who actually took part.

Started

May 2024

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of multiple sclerosis (MS) * Clinically and radiologically stable MS in the previous 3 months * Age between 18 and 60 years * Positive finding for oligoclonal bands (OCBs) * Written consent * Blood collection at the beginning and end of the study for routine parameter examination as well as sample preservation (especially for measuring propionic acid levels) * Negative pregnancy test for female participants of childbearing age Exclusion Criteria: * Existing propionic acid supplementation * Change in disease-modifying therapy (DMT) in the previous 4 weeks * Existing severe systemic diseases * Presence of other concomitant structural nerve diseases (e.g., polyneuropathy, brain tumor, strokes) * High JCV titer under Natalizumab

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Disease Progression Fatigue multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis

Contacts and locations

Locations

  • Salzburger Landeskliniken

    Salzburg, State of Salzburg, 5020, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.